Clinical Trials

42 enrolled

Gastric Cancer Peritoneal Metastases

NCT05638451 2024-06-05

Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients

Glioblastoma

NCT05685836 2024-03-20

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Unknown

15 enrolled

Neuroma, Acoustic, Neurofibromatosis 2

NCT01910610 2024-03-12

STRATEGIC-1

464 enrolled

Colorectal Cancer Metastatic

NCT04739670 2024-03-01

BELLA

31 enrolled

Breast

Recurrence, Triple Negative Breast Neoplasms

NCT06285019 2024-02-29

Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma

65 enrolled

Carcinoma, Hepatocellular

NCT06269445 2024-02-21

The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer

Phase 4 Unknown

20 enrolled

Colorectal Neoplasms

NCT05173298 2024-02-07

HCC

Unknown

100 enrolled

Carcinoma, Hepatocellular

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05296278 2024-01-10

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05906524 2024-01-10

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Phase 1/2 Unknown

85 enrolled

Other solid neoplasm

Advanced HCC

NCT03647592 2023-12-27

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Unknown

Carcinoma, Non-Small-Cell Lung

NCT06182800 2023-12-27

Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04395989 2023-12-22

FUTURE-SUPER

139 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06177288 2023-12-20

DEBIRI

Phase NA Unknown

39 enrolled

Colorectal Neoplasms

NCT05833126 2023-12-15

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

25 enrolled

Recurrent Liver Cancer After Liver Transplantation

NCT04034459 2023-11-14

AIO-KRK-0116

109 enrolled

Colorectal Neoplasms

NCT04310176 2023-11-13

REVOLUTION

200 enrolled

Colorectal Neoplasms

NCT05785325 2023-10-31

RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer

Colorectal Neoplasms

NCT06060704 2023-10-11

Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.

33 enrolled

Colorectal Neoplasms

NCT03818061 2023-09-28

ATHENA

33 enrolled

Head & Neck

Head and Neck Neoplasms

NCT06039202 2023-09-15

Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer

100 enrolled

Colorectal Neoplasms

NCT06003998 2023-08-22

INTERACT-II

85 enrolled

Colorectal Neoplasms

NCT04262687 2023-08-18

POCHI

55 enrolled

Colorectal Cancer Metastatic

NCT04659382 2023-08-18

SIRTCI

52 enrolled

Colorectal Neoplasms

NCT03961698 2023-08-14

MARIO-3

91 enrolled

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT03363867 2023-08-07

BEACON

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03950154 2023-08-01

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer

198 enrolled

Colorectal Neoplasms

NCT04724239 2023-08-01

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

48 enrolled

Colorectal Neoplasms

NCT05965154 2023-07-28

Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma

22 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04201561 2023-06-26

SELENIUM

68 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT05904457 2023-06-15

BRISK

32 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05191784 2023-06-12

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

20 enrolled

Glioblastoma

NCT05160896 2023-06-08

SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

90 enrolled

Advanced Metastatic Colorectal Cancer

NCT05886465 2023-06-02

HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

40 enrolled

Carcinoma, Hepatocellular

NCT05799820 2023-05-25

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

60 enrolled

Colorectal Neoplasms

NCT05819060 2023-04-19

The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab

44 enrolled

Ovarian Neoplasms

NCT05811793 2023-04-13

Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.

Phase NA Unknown

36 enrolled

Glioblastoma

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

228 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05792410 2023-03-31

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

Phase 1/2 Unknown

300 enrolled

Breast

Breast Neoplasms

NCT04974879 2023-03-29

Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer

20 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05104281 2023-03-29

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

60 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05267288 2023-03-29

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

PFS

NCT01706120 2023-03-24

MITO16/MANGO-2

Phase 4 Unknown

400 enrolled

Ovarian Neoplasms

NCT01802749 2023-03-24

MITO16MANGO2b

406 enrolled

Ovarian Neoplasms

NCT02633189 2023-03-24

BEVERLY

200 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT05616390 2023-03-21

Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT03654833 2023-03-14

MiST

Other solid neoplasmThoracic

186 enrolled

Mesothelioma, Malignant

NCT02761070 2023-03-08

RE-GEND

146 enrolled

Glioblastoma, Recurrence, Disease Progression

NCT05760599 2023-03-08

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T